Comparative Pharmacology
Head-to-head clinical analysis: DESONATE versus HC 1.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DESONATE versus HC 1.
DESONATE vs HC #1
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Desonide is a corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties. It acts by inducing phospholipase A2 inhibitory proteins, thereby reducing arachidonic acid release and subsequent prostaglandin and leukotriene synthesis.
Unknown
Apply 0.05% cream, lotion, or ointment topically to affected skin twice daily.
Hydrocortisone: 100-200 mg IV as initial dose, then 50-100 mg IV every 6 hours, or 0.18 mg/kg/h IV continuous infusion.
None Documented
None Documented
Terminal half-life is approximately 3-4 hours for desonide; clinically, this supports twice-daily dosing.
2–4 hours (terminal); prolonged in renal impairment.
Renal (approximately 75% as metabolites, <5% unchanged) and fecal (approximately 25%).
Renal: 90% as unchanged drug; fecal: 10%.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid